Alzheimer hastalığının erken teşhisi: Gelişmeler, zorluklar ve geleceğe bakış

Abstract

Alzheimer hastalığı, bireyin bağımsızlığını ve hafıza yetilerini giderek daha fazla kısıtlayan, ilerleyici bir hastalıktır ve şu an için kesin bir tedavisi bulunmamaktadır. Hastalığın ilerleyişini yavaşlatabilmek için erken teşhis hayati önem taşımaktadır. Ancak, mevcut müdahale yöntemleri çeşitli riskler taşıyabilirken, beyin görüntüleme, belden sıvı alma (lomber ponksiyon) ve bilişsel değerlendirmeler gibi standart teşhis yöntemleri de genellikle maliyetli, invaziv (girişimsel) ve her zaman erişilebilir değildir. Son dönemde kan biyobelirteçleri, özellikle de amiloid-beta ve tau proteinleri üzerine yapılan çalışmalar, bu sorunlara daha az invaziv, daha uygun maliyetli ve ölçeklenebilir bir alternatif sunmaktadır. Bu makale, Alzheimer hastalığı için mevcut kan bazlı teşhis testlerinin geçerliliğini, pratikliğini ve sınırlılıklarını değerlendirmektedir. Çalışmada hem teknik zorluklara hem de eşit erişim ve bilgilendirilmiş onam gibi etik konulara değinilmektedir. Yeni tedavilerin ortaya çıkışı, doğru ve zamanında teşhisin önemini daha da artırmaktadır. Kan testleri, Alzheimer teşhisinde büyük bir potansiyel barındırsa da, yaygın olarak benimsenmeleri önünde bazı engeller bulunmaktadır. Bunlar arasında daha yüksek doğruluk oranına ihtiyaç duyulması, bu testlerin sadece özel kliniklerle sınırlı kalmayıp daha geniş kitlelere ulaşması ve farklı sağlık hizmeti ortamlarına kolayca uyarlanabilmesi gerekliliği yer almaktadır. Bu derleme, kan bazlı teşhis yöntemlerinin ölçeklenebilirliğini ve erişilebilirliğini artırmaya yönelik stratejileri belirlemekte ve bunların uygulanması için atılması gereken adımları ortaya koymaktadır. Süregelen teknolojik ve lojistik gelişmelerle birlikte, kan testlerinin gelecekte Alzheimer hastalığı teşhisinde çığır açacağı öngörülmektedir.

Keywords

• Alzheimer hastalığı
• kan temelli biyobelirteçler
• amiloid-beta
• tau proteinleri
• erken teşhis
• teşhis erişilebilirliği

Early detection of Alzheimer’s disease: Progress, challenges, and future outlook

Abstract

Alzheimer's disease progressively impairs independence and memory, and no cure is currently available. Early diagnosis is crucial for slowing disease progression; however, existing interventions may pose risks, and standard diagnostic methods, such as brain imaging, lumbar puncture, and cognitive assessments, are often expensive, invasive, or inaccessible. Recent advances in blood biomarkers, including amyloid-beta and tau proteins, present a less invasive, more cost-effective, and scalable alternative. This review evaluates the validity, practicality, and limitations of current blood-based diagnostic tests for Alzheimer's disease. It addresses both technical challenges and ethical considerations, including equitable access and informed consent. The emergence of new treatments further underscores the importance of accurate and timely diagnosis. Although blood tests demonstrate significant potential for Alzheimer's diagnosis, their widespread adoption is constrained by requirements for improved accuracy, broader availability beyond specialized clinics, and adaptability to diverse healthcare environments. This review identifies strategies to enhance the scalability and accessibility of blood-based diagnostics and outlines subsequent steps for implementation. With continued technological and logistical advancements, blood-based tests could transform the landscape of Alzheimer's diagnosis.

Keywords

• Alzheimer's disease
• blood-based biomarkers
• amyloid-beta
• tau proteins
• early diagnosis
• diagnostic accessibility

References

1. [1]     Alzheimer’s Disease International. “World Alzheimer Report 2024: Global changes in attitudes to dementia”, https://www.alzint.org/u/World-Alzheimer-Report-2024.pdf (18.03.2025).
2. [2]     Better MA. “Alzheimer’s disease facts and figures”. Alzheimer's Dement, 19(4), 1598-1695, 2023.
3. [3]     Cummings J, Lee G, Zhong K, Fonseca J, Taghva K. “Alzheimer’s disease drug development pipeline: 2021”, Alzheimer's Dement Transl Res Clin Interv, 7(1), e12179, 2021.
4. [4]     Nehra G, Bauer B, Hartz AM. “Blood-brain barrier leakage in Alzheimer’s disease: From discovery to clinical relevance”. Pharmacol Ther, 234, 108119, 2022.
5. [5]     Hemmy LS, Linskens BS, Silverman PC, Miller MA, Talley KMC, Taylor BC, et al. “Brief Cognitive Tests for Distinguishing Clinical Alzheimer-Type Dementia From Mild Cognitive Impairment or Normal Cognition in Older Adults With Suspected Cognitive Impairment: A Systematic Review”. Ann Intern Med, 172(10), 678-687, 2020.
6. [6]     Lorking N, Murray AD, O’Brien JT. “The use of positron emission tomography/magnetic resonance imaging in dementia: A literature review”. Int J Geriatr Psychiatry, 36(10), 1501-1513, 2021.
7. [7]     Jack CR, Andrew JS, Beach TG, Buracchio T, Dunn B, Graf A, et al. “Revised criteria for diagnosis and staging of Alzheimer’s disease: Alzheimer’s Association Workgroup”. Alzheimer's Dement, 20(8), 5143-5169, 2024.
8. [8]     Dubois B, Villain N, Frisoni GB, Rabinovici GD, Sabbagh M, Cappa S, et al. “Clinical diagnosis of Alzheimer’s disease: recommendations of the International Working Group”. Lancet Neurol, 20(6), 484-496, 2021.

9. [9]     Kang B, Ma J, Jeong I, Yoon S, Kim JI, Heo SJ, et al. “Behavioral marker-based predictive modeling of functional status for older adults with subjective cognitive decline and mild cognitive impairment: Study protocol”. Digit Health, 10, 20552076241269555, 2024.
10. [10]  Tsai CF, Lee WJ, Wang SJ, Shia BC, Nasreddine Z, Fuh JL. “Psychometrics of the Montreal Cognitive Assessment (MoCA) and its subscales: validation of the Taiwanese version of the MoCA and an item response theory analysis”. Int Psychogeriatr, 24(4), 651-658, 2012.
11. [11]  Lee JY, Lee DW, Cho SJ, Na DL, Jeon HJ, Kim SK, et al. “Brief Screening for Mild Cognitive Impairment in Elderly Outpatient Clinic: Validation of the Korean Version of the Montreal Cognitive Assessment”. J Geriatr Psychiatry Neurol, 21(2), 104-110, 2008.
12. [12]  Geller R, Slicer K. Montreal Cognitive Assessment (MoCA). Editors: Golden CJ, Bennet R. Clinical Integration of Neuropsychological Test Results, 191-204, CRC Press, USA, 2024.
13. [13]  Ding Z, Lee TL, Chan AS. “Digital cognitive biomarker for mild cognitive impairments and dementia: a systematic review”. J Clin Med, 11(14), 4191, 2022.
14. [14]  Randolph C, Tierney MC, Mohr E, Chase TN. “The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS): Preliminary Clinical Validity”. J Clin Exp Neuropsychol, 20(3), 310-319, 1998.
15. [15]  Grueso S, Viejo-Sobera R. “Machine learning methods for predicting progression from mild cognitive impairment to Alzheimer’s disease dementia: a systematic review”. Alzheimer's Res Ther, 13(1), 162, 2021.
16. [16]  Jarek DJ, Mizerka H, Nuszkiewicz J, Szewczyk-Golec K. “Evaluating p-tau217 and p-tau231 as biomarkers for early diagnosis and differentiation of Alzheimer’s Disease: a narrative review”. Biomedicines, 12(4), 786, 2024.
17. [17]  Rabinovici GD, Furst AJ, Alkalay A, Racine CA, O'Neil JP, Janabi M, et al. “Increased metabolic vulnerability in early-onset Alzheimer’s disease is not related to amyloid burden”. Brain, 133(2), 512-528, 2010.
18. [18]  van Oostveen WM, de Lange EC. “Imaging techniques in Alzheimer’s disease: a review of applications in early diagnosis and longitudinal monitoring”. Int J Mol Sci, 22(4), 2110, 2021.
19. [19]  Hu Y, Cho M, Sachdev P, Dage J, Hendrix S, Hansson O, et al. “Fluid biomarkers in the context of amyloid-targeting disease-modifying treatments in Alzheimer’s disease”. Med, 5(10), 1206-1226, 2024.
20. [20]  Jack CR, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, et al. “NIA‐AA Research Framework: Toward a biological definition of Alzheimer’s disease”. Alzheimer's Dement, 14(4), 535-562, 2018.
21. [21]  Jesus Jr B, Cassani R, McGeown WJ, Cecchi M, Fadem KC, Falk TH. “Multimodal prediction of Alzheimer’s disease severity level based on resting-state EEG and structural MRI”. Front Hum Neurosci, 15, 700627, 2021.
22. [22]  Van Broeckhoven CL. “Molecular genetics of Alzheimer's disease: identification of genes and gene mutations”. Eur Neurol, 35(1), 8-19, 1995.
23. [23]  Vann KT, Xiong ZG. “Optogenetics for neurodegenerative diseases”. Int J Physiol Pathophysiol Pharmacol, 8(1), 1-8, 2016.
24. [24]  Benussi A, Di Lorenzo F, Dell'Era V, Cosseddu M, Alberici A, Caratozzolo S, et al. “Transcranial magnetic stimulation distinguishes Alzheimer disease from frontotemporal dementia”. Neurology, 89(7), 665-672, 2017.
25. [25]  Chaparro CI, Simões BT, Borges JP, Castanho MA, Soares PI, Neves V. “A promising approach: magnetic nanosystems for Alzheimer’s disease theranostics”. Pharmaceutics, 15(9), 2316, 2023.
26. [26]  McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. “Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease”. Neurology, 34(7), 939–944, 1984.
27. [27]  McKhann GM, Knopman DS, Chertkow HJ, Hyman BT, Jack Jr CR, Kawas CH, et al. “The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging‐Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease”. Alzheimer's Dement, 7(3), 263-269, 2011.
28. [28]  Palmqvist S, Janelidze S, Quiroz YT, Zetterberg H, Lopera F, Stomrud E, et al. “Discriminative accuracy of plasma phospho-tau217 for Alzheimer disease vs other neurodegenerative disorders”. JAMA, 324(8), 772-781, 2020.
29. [29]  Diagnostics Q. “Quest Introduces First-to-Market Consumer-Initiated Blood Test for Alzheimer’s Disease Risk Assessment on Questhealth. Com”, P https://newsroom.questdiagnostics.com/2023-07-31-Quest-Introduces-First-To-Market-Consumer-Initiated-Blood-Test-for-Alzheimers-Disease-Risk-Assessment-on-questhealth-com (18.03.2025).
30. [30]  Teunissen CE, Verberk IMW, Thijssen EH, Vermunt L, Hansson O, Zetterberg H, et al. “Blood-based biomarkers for Alzheimer’s disease: towards clinical implementation”. Lancet Neurol, 21(1), 66-77, 2022.
31. [31]  Hampel H, Hu Y, Cummings J, Mattke S, Iwatsubo T, Nakamura A, et al. “Blood-based biomarkers for Alzheimer’s disease: Current state and future use in a transformed global healthcare landscape”. Neuron, 111(18), 2781-2799, 2023.
32. [32]  Sun Y, Wang P, Zhao K, Chen P, Qu Y, Li Z, et al. “Structure–function coupling reveals the brain hierarchical structure dysfunction in Alzheimer’s disease: A multicenter study”. Alzheimer's Dement, 20(9), 6305-6315, 2024.
33. [33]  Gomes NDP. Development of neuroprotective lipid nanocarriers for Alzheimer’s disease. PhD Thesis, University of Minho, Braga, Portugal, 2023
34. [34]  Escalante AG, Milà-Alomà M, Brum WS, Ashton NJ, Ortiz-Romero P, Shekari M, et al. “A Plasma Biomarker Panel for Detecting Early Amyloid-B Accumulation and its Changes in Middle-Aged Cognitively Unimpaired Individuals at Risk for Alzheimer’s Disease”. EbioMedicine, 116, 105741, 2025.
35. [35]  Van Dyck CH, Swanson CJ, Aisen P, Bateman TJ, Chen C, Gee M, et al. “Lecanemab in Early Alzheimer’s Disease”. N Engl J Med, 388(1), 9-21, 2023.
36. [36]  Mintun MA, Lo AC, Evans CD, Wessels AM, Ardayfio PA, Andersen SW, et al. “Donanemab in Early Alzheimer’s Disease”. N Engl J Med, 384(18), 1691-1704, 2021.
37. [37]  Livingston G, Huntley J, Sommerlad A, Ames D, Ballard C, Banerjee S, et al. “Dementia prevention, intervention, and care: 2020 report of the Lancet Commission”. The Lancet, 396(10248), 413-446, 2020.
38. [38]  Schöll M, Verberk IMW, Del Campo M, Delaby C, Therriault J, Chong JR, et al. “Challenges in the practical implementation of blood biomarkers for Alzheimer’s disease”. Lancet Healthy Longev, 5(10), 100630, 2024.
39. [39]  Hamilton J. “New blood tests can help diagnose Alzheimer’s. Are doctors ready for what’s next?”. https://www.npr.org/sections/shots-health-news/2024/08/02/g-s1-14852/alzheimers-new-blood-tests-amyloid-tau-ptau217-diagnosis (26.05.2025).
40. [40]  Farvadi F, Hashemi F, Amini A, Vakilinezhad MA, Raee MJ. “Early Diagnosis of Alzheimer’s Disease with Blood Test; Tempting but Challenging”. Int J Mol Cell Med, 12(2), 172, 2023.
41. [41]  UCHealth Today. “New blood tests for Alzheimer’s may allow for earlier detection of the terrible disease. But how much will Alzheimer’s blood tests cost, and who should get them?”. https://www.uchealth.org/today/new-blood-tests-for-alzheimers-may-allow-for-earlier-detection/ (26.05.2025).
42. [42]  Leuzy A, Mattsson‐Carlgren N, Palmqvist S, Janelidze S, Dage JL, Hansson O. “Blood‐based biomarkers for Alzheimer’s disease”. EMBO Mol Med, 14(1), e14408, 2022.
43. [43]  Palmqvist S, Tideman P, Mattsson-Carlgren N, Schindler SE, Smith R, Ossenkoppele R, et al. “Blood biomarkers to detect Alzheimer's disease in primary care and secondary care”. JAMA, 332(15), 1245-1257, 2024.
44. [44]  Peralta Walker SC. Assessing Blood-Based Laboratory Diagnostics for Alzheimer’s Disease: A Systems Approach. PhD Thesis, Massachusetts Institute of Technology, Cambridge, USA, 2025.
45. [45]  Thijssen EH, La Joie R, Strom A, Fonseca C, Iaccarino L, Wolf A, et al. “Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer’s disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study”. Lancet Neurol, 20(9), 739-752, 2021.
46. [46]  Ketchum FB. “Lessons Learned: Social and Ethical Issues Related to Clinical Implementation of Blood‐Based Biomarkers for Alzheimer’s Disease”. Alzheimer's Dement, 20(S4), e089279, 2024.
47. [47]  Hansson O, Edelmayer RM, Boxer AL, Carrillo MC, Mielke MM, Rabinovici GD, et al. “The Alzheimer’s Association appropriate use recommendations for blood biomarkers in Alzheimer’s disease”. Alzheimer's Dement, 18(12), 2669-2686, 2022.
48. [48]  Schermer MHN, Richard E. “On the reconceptualization of Alzheimer’s disease”. Bioethics, 33(1), 138-145, 2019.
49. [49]  Alzheimer’s Association. “Alzheimer’s blood tests could improve diagnosis.”. https://aaic.alz.org/releases-2024/blood-tests-alzheimers-biomarkers.asp (29.05.2025).
50. [50]  Assfaw AD, Schindler SE, Morris JC. “Advances in blood biomarkers for Alzheimer's disease (AD): A review”. Kaohsiung J Med Sci, 40(8), 692-698, 2024.
51. [51]  Schindler SE, Bateman RJ. “Combining blood-based biomarkers to predict risk for Alzheimer’s disease dementia | Nature Aging”. Nature Aging, 1, 26-28, 2021.
52. [52]  Ketchum FB. “Dementia Care Research and Psychosocial Factors”. Alzheimer's Dement J Alzheimers Assoc, 20, e089279, 2024.